Buy ADB-FUBINACA Powder
Firstly Buy ADB-FUBINACA Powder is a designer drug identify synthetic cannabis blends in Japan in 2013. Secondly In 2018, it was the third-most common synthetic cannabinoid identify in drugs seize by the Drug Enforcement Agency.
Also the (S)-enantiomer of ADB-FUBINACA is describ in a 2009 Pfizer patent and has been report to be a potent agonist of the CB1 receptor and the CB2 receptor with EC50 values of 1.2 nM and 3.5 nM, respectively. Moreso ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. In addition ADB-FUBINACA appears to be the product of rational drug design and since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
Further an analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently report.
Formal Name: N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
CAS Number: 1445583-51-6
Molecular Formula: C21H23FN4O2
Formula Weight: 382.4
Formulation: A neat solid
InChi Key: ZSSGCSINPVBLQD-UHFFFAOYSA-N
DEA Schedule: I
Shipping & Storage Information
Shipping: Room Temperature in continental US; may vary elsewhere
Stability: ? 3 years
In the United States, ADB-FUBINACA is a Schedule I control substance.
Twenty-three ADB-FUBINACA major metabolites were identify in several incubations with cryopreserved human hepatocytes. Subsequently major metabolic pathways were alkyl and indazole hydroxylation, terminal amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation
meanwhile One death through coronary arterial thrombosis has been link to ADB-FUBINACA intoxication.
Furthermore at least an additional 8 deaths in Hungary in 2015 are link to the usage of this material, all deaths were youngsters below 21.
WARNING Lastly this product is not for human or veterinary use.